2024-01-22 17:13:06 ET
Summary
- Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price.
- The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock.
- The Q&A session provided some insights, including information about utilization management headwinds and the company's digital consumer campaign.
- Altogether, the company appears to be stuck in a "prove it" box and needs to demonstrate a compelling path to profitability to maintain interest in investing in the promise of its drugs.
A Surprise Secondary
What do you do when a company rolls out a massive stock offering within weeks of reassuring investors about its cash position and path to profitability? It depends on the subsequent price action. In the case of Michigan-based pharmaceutical company Esperion Therapeutics ( ESPR ), so far so good as the stock gapped down after news of a stock offering but never reached the offering price of $1.50/share . (Read Seeking Alpha article “ Esperion Is Sitting On A Potential Blockbuster Drug ” for a primer on the company and its key cardiovascular drugs)....
Read the full article on Seeking Alpha
For further details see:
Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations